Rheumatoid Arthritis Clinical Trial
Official title:
A Phase II, Multicenter, Double-blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Intravenous Natalizumab (300 mg) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Receiving Concomitant Treatment With Methotrexate (MTX)
NCT number | NCT00083759 |
Other study ID # | ELN100226-RA201 |
Secondary ID | |
Status | Terminated |
Phase | Phase 2 |
First received | June 1, 2004 |
Last updated | July 14, 2016 |
Start date | May 2004 |
Verified date | April 2009 |
Source | Biogen |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to determine the safety, tolerability and efficacy of natalizumab in subjects diagnosed with moderate to severe rheumatoid arthritis (RA) receiving concomitant treatment with methotrexate (MTX). It is thought that natalizumab may stop the movement of certain white blood cells, known as lymphocytes, into joint tissue. These cells are thought to cause damage in the joints leading to the symptoms of RA.
Status | Terminated |
Enrollment | 299 |
Est. completion date | |
Est. primary completion date | February 2005 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: Subjects will be eligible to begin study participation if they meet all of the following inclusion criteria: - Subject is able to read, understand, and voluntarily sign the approved Informed Consent form prior to the performance of any study-specific procedures; - Male or female subjects, =18 to =75 years of age, who has a diagnosis of rheumatoid arthritis Functional Class 1 to 3 by the 1987 Revised American Rheumatism Association Criteria for the Classification of Rheumatoid Arthritis for at least 6 months prior to screening; - Subject is on a stable dose of MTX of at least 10 mg/week for =3 months prior to randomization (Month 0) without an adequate response; - Female subjects of childbearing potential agree to use adequate, contraceptive methods (either intrauterine device [IUD], oral or depot contraceptive, or barrier plus spermicide). Female subjects of childbearing potential use adequate contraception for at least 2 months prior to study entry and continue contraception for at least 3 months after their last infusion of study drug; - Subject is willing and able to complete all planned study procedures; - Subject has at least 10 painful/tender and 6 swollen joints at the Month 0 (Baseline) visit; - Subject has an elevated CRP level (defined as >2.87 mg/L) at Screening. Exclusion Criteria: Subjects will be excluded from the study if they meet any of the following exclusion criteria: - Subject is pregnant or lactating; - Subject who has experienced an inadequate therapeutic response after at least 3 months of treatment with at least one TNF-alpha inhibitor; - Subject who has received treatment with anakinra; - Subject who has received prior treatment with natalizumab; - Subject does not meet the following criteria regarding concomitant medications for RA: - Use of any oral steroid exceeding 10 mg/day of prednisone (or equivalent dose) and not administered at a stable dose for at least 1 month prior to randomization (Month 0); - Use of any NSAIDs unless stable for at least 1 month prior to randomization (Month 0); - Use of other anti-arthritic treatments, including approved or experimental oral, topical, or injectable biologics or drugs, or devices within 1 month prior to randomization (Month 0); - Intra-articular corticosteroid injections within 1 month prior to randomization (Month 0); - Treatment with any TNF-alpha inhibitor within 2 months prior to randomization (Month 0); - Subject who is expected to be unavailable for the duration of the trial, likely to be noncompliant with the Protocol, or felt to be unsuitable by the Investigator for any other reason; - Subject who has a history of a malignancy (other than basal cell carcinoma of the skin); - Subject who has a history of clinically significant and/or persistent gastrointestinal, pulmonary, chronic infection, cardiovascular, renal, hepatic, neurological, dermatological, immunological, major psychiatric (including drug or alcohol abusers) or hematological illness, which, in the opinion of the Investigator placed the subject at unacceptable risk for participation in the study; - Subject who has any laboratory test at Screening considered significantly abnormal. An alanine transaminase (ALT) or aspartate transaminase (AST) =1.5 x upper limits of normal (ULN) and cytopenia (included any of the following: WBC <3.5 x 1000/uL; hemoglobin [Hb] <8 g/dL; platelets <100 x 1000/uL; and/or neutrophils absolute <1.0 x 1000/uL) were considered significantly abnormal; - Subject who intends to donate blood or blood products during the period of the study or within 1 month following completion of the study; - Subject who has a positive tuberculosis (TB) skin test at Screening or within the 30 days prior to Screening (defined as =10 mm induration); - Subject who plans or requires any surgical procedure during the study treatment period. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | The Arthritis Program Research Group Inc. | Newmarket | Ontario |
Canada | St. Clare's Mercy Hospital | St. John's | Newfoundland and Labrador |
United States | University of Alabama at Birmingham | Birmingham | Alabama |
United States | Massachusetts General Hospital | Boston | Maine |
United States | Radiant Research | Dallas | Texas |
United States | Altoona Center for Clinical Research | Duncansville | Pennsylvania |
United States | Arthritis Medical Clinic of North County, Inc. | Escondido | California |
United States | Jacksonville Center for Clinical Research | Jacksonville | Florida |
United States | Justus Fiechtner, MD, PC | Lansing | Michigan |
United States | Clinical Research Unit / University of Arizona | Tucson | Arizona |
United States | Rheumatic Disease Associates | Willow Grove | Pennsylvania |
United States | Clinical Pharmacology Study Group | Worcester | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Biogen | Elan Pharmaceuticals |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | American College of Rheumatology (ACR)20. | =20% reduction from baseline in painful/tender joint count and swollen joint count and =20% improvement in at least three of five secondary clinical parameters (e.g., subject global assessment, physician global assessment, pain scale, disability score, and an acute phase reactant) | Month 6 | No |
Secondary | American College of Rheumatology (ACR)50 | =50% reduction from baseline in painful/tender joint count and swollen joint count and =50% improvement in at least three of five secondary clinical parameters (e.g., subject global assessment, physician global assessment, pain scale, disability score, and an acute phase reactant) | Month 6 | No |
Secondary | American College of Rheumatology (ACR)70 | =70% reduction from baseline in painful/tender joint count and swollen joint count and =70% improvement in at least three of five secondary clinical parameters (e.g., subject global assessment, physician global assessment, pain scale, disability score, and an acute phase reactant) | Month 6 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |